Q-omics provides the consensus-scored SPDYE2B profile across patient tissues and cancer cell-line models. SPDYE2B expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SPDYE2B is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, SPDYE2B RNA expression shows 7,234 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, HNSC, and KIRP as cancer lineages where SPDYE2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDYE2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDYE2B survival associations across molecular data types. SPDYE2B RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDYE2B RNA expression–survival associations across cancer types. High SPDYE2B expression shows unfavorable associations in KICH, COAD, UCEC and LUSC, but favorable associations in LIHC and PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for SPDYE2B RNA expression.
This table summarizes SPDYE2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPDYE2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDYE2B shows higher tumor expression in HNSC, BRCA and CHOL. The HNSC box plot shows higher SPDYE2B RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p = .027).
This table shows molecular features associated with SPDYE2B in patient tissues and cancer cell lines. In patient samples, SPDYE2B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SPDYE2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
